Get started
Author

Gabriel Mak

Observed names: G Mak, G. Mak, Gabriel W. H. Mak, Mak, G, Mak, G.
Observed institutions: Sarah Cannon Research Institute, The Alfred Hospital, UNSW Sydney, Prince of Wales Hospital, Prince of Wales Hospital, AstraZeneca (United States), University College London
OpenAlex ID: A5114095234
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
2019 · Gabriel Mak, Jean-Charles Soria, et al. · British Journal of Cancer · 98
PDF
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
2019 · Suresh Senan, Isamu Okamoto, et al. · Clinical Lung Cancer · 71
Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
2017 · Michele Moschetta, Mario Uccello, et al. · BioMed Research International · 66
PDF
Prospective analysis of 895 patients on a UK Genomics Review Board
2019 · David Allan Moore, Marina Kushnir, et al. · ESMO Open · 32
Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma
2017 · Lipika Goyal, Hendrik-Tobias Arkenau, et al. · Annals of Oncology · 22
Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation
2014 · Gabriel Mak, Melvin Chin, et al. · BMC Research Notes · 17
PDF
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study
2016 · Emily Y. He, Nicholas J. Hawkins, et al. · The Oncologist · 16
PDF
OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04
2023 · K.P. Papadopoulos, D. Bruno, et al. · Journal of Thoracic Oncology · 15
PDF
Towards an Optimal Treatment Algorithm for Metastatic Pancreatic Ductal Adenocarcinoma (PDA)
2018 · M. Uccello, M. Moschetta, et al. · Current Oncology · 15
PDF
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours
2017 · Noelia Nebot, Hendrik‐Tobias Arkenau, et al. · British Journal of Clinical Pharmacology · 15
PDF
ADRIATIC: A phase III trial of durvalumab ± tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer
2019 · S. Senan, N. Shire, et al. · Annals of Oncology · 12
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
2018 · H.-T. Arkenau, A. Italiano, et al. · European Journal of Cancer · 12
PDF
Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
2017 · Michele Moschetta, Gabriel Mak, et al. · Experimental Hematology and Oncology · 12
PDF
TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).
2023 · Hossein Borghaei, Saiama Naheed Waqar, et al. · Journal of Clinical Oncology · 10
Local perspective on a rare brain tumour: adult medulloblastoma
2012 · S. F. Wong, G. Mak, et al. · Internal Medicine Journal · 10
Immunotherapy in Colorectal Cancer
2016 · Gabriel Mak, Michele Moschetta, et al. · InTech eBooks · 9
PDF
Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
2014 · Gabriel Mak, Hendrik-Tobias Arkenau, et al. · Melanoma Research · 8
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
2015 · Hendrik-Tobias Arkenau, Anas Gazzah, et al. · Journal of Clinical Oncology · 7
Reporting incidental germline variants in the context of day-to-day somatic genomic profiling
2016 · G. Mak, M. Moschetta, et al. · Annals of Oncology · 3
PDF
Use of neostigmine in capecitabine-induced paralytic ileus
2013 · Gabriel Mak, Robyn Ward, et al. · Tumori Journal · 3
Durvalumab in combination with chemoradiotherapy in patients with head and neck squamous cell carcinoma: Results from the Phase 1 CLOVER study
2024 · Julie E. Bauman, Sana D. Karam, et al. · Head & Neck · 2
PDF
Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition
2016 · M. Moschetta, B. Kasenda, et al. · Annals of Oncology · 2
PDF
Long Survival (Cure) to Cisplatin/Infusional 5-Flurouracil in Metastatic Squamous Cell Anal Cancer with Extensive Liver and Lung Metastases
2015 · Andrew Haydon, Rebecca Tay, et al. · Case Reports in Clinical Medicine · 1
PDF
ADRIATIC: Eine Phase-III-Studie mit Durvalumab ± Tremelimumab nach gleichzeitiger Radiochemotherapie für Patienten mit SCLC im Stadium Limited Disease
2020 · F Griesinger, S Senan, et al. · Pneumologie
Adriatic: a Phase III Trial of Durvalumab plus /- Tremelimumab After Concurrent Chemoradiation for Patients with Limited Stage Small Cell Lung Cancer
2020 · Griesinger, F., Senan, S., et al. · Pure Amsterdam UMC
Works count: 35
Citation count: 458
H-index: 12
I10-index: 15
Year
Topic
Type